References
- Sneed T B, Kantarjian H M, Talpaz M, O'Brien S, Rios M B, Bekele B N, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myeloid leukemia in chronic phase. Cancer 2004; 100: 116–121
- Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of Abl tyrosine kinase on the growth of bcr abl positive cells. Nat Med 1996; 2: 561–566
- Bartolovic K, Hartmann U, Balabanov S, et al. Expansion potential and colony forming capacity of normal CD 34+ cells is impaired by treatment with imatinib mesylate in vitro. (Suppl. Blood) 2002; 100: 584a
- Cavanna L, Vallisa D, Berte R, Buscarini E, Fornari F, Di Stasi M, et al. Severe immune thrombocytopenic purpura relapse after α-interferon in chronic myeloid leukemia, successfully treated with cyclosporine. Am J Hematol 1994; 47: 255–256
- Herishanu Y, Trestmen S, Kirgner I, Rachmani R, Naparstek E. Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-α: differential diagnosis and possible pathogenesis. Leuk Lymphoma 2003; 44: 2103–2108
- Kantarjian H M, Sawyer C, Hochhaus A, et al. Hematologic and cytogenetic response to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002; 346: 645–652
- Wazny L D, Ariano R E. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20: 292–307
- Hackett T, Kelton J G, Powers P. Drug-induced platelet destruction. Semin Thromb Hemost 1982; 8: 116–137
- Aster R H. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999; 36: 2–6
- Ball P. Thrombocytopenia and purpura in patients receiving chlorothiazide and hydrochlorothiazide. JAMA 1960; 173: 663–665
- Duncan A, Moore S B, Barker P. Thrombocytopenia caused by frusemide-induced platelet antibody. Lancet 1981; 1: 1210
- Novaretti M CZ, Fonseca G HH, Conchon M, Dorlhiac-Llacer P E. First case of immune mediated hemolytic anemia associated to imatinib. Eur J Hematol 2003; 71: 455–458